- Home
- KDLY vs ONVO Comparison
KDLY vs ONVO Comparison
Compare KDLY & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KDLY
- ONVO
- Stock Information
- Founded
- KDLY 2019
- ONVO 2007
- Country
- KDLY United States
- ONVO United States
- Employees
- KDLY N/A
- ONVO N/A
- Industry
- KDLY
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KDLY
- ONVO Health Care
- Exchange
- KDLY NYSE
- ONVO Nasdaq
- Market Cap
- KDLY 7.8M
- ONVO 6.5M
- IPO Year
- KDLY 2024
- ONVO N/A
- Fundamental
- Price
- KDLY $1.44
- ONVO $0.35
- Analyst Decision
- KDLY
- ONVO
- Analyst Count
- KDLY 0
- ONVO 0
- Target Price
- KDLY N/A
- ONVO N/A
- AVG Volume (30 Days)
- KDLY 87.4K
- ONVO 245.2K
- Earning Date
- KDLY 02-03-2025
- ONVO 02-06-2025
- Dividend Yield
- KDLY N/A
- ONVO N/A
- EPS Growth
- KDLY N/A
- ONVO N/A
- EPS
- KDLY N/A
- ONVO N/A
- Revenue
- KDLY $2,875,400.00
- ONVO $103,000.00
- Revenue This Year
- KDLY N/A
- ONVO $59.08
- Revenue Next Year
- KDLY N/A
- ONVO $18.24
- P/E Ratio
- KDLY N/A
- ONVO N/A
- Revenue Growth
- KDLY N/A
- ONVO N/A
- 52 Week Low
- KDLY $0.65
- ONVO $0.32
- 52 Week High
- KDLY $4.20
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- KDLY N/A
- ONVO 43.13
- Support Level
- KDLY N/A
- ONVO $0.34
- Resistance Level
- KDLY N/A
- ONVO $0.51
- Average True Range (ATR)
- KDLY 0.00
- ONVO 0.06
- MACD
- KDLY 0.00
- ONVO -0.00
- Stochastic Oscillator
- KDLY 0.00
- ONVO 9.67
About KDLY KINDLY MD INC
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.